View Clinical Trial (Medical Research Study)

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease - NCT00205231-53792(Clinical Trial 130188)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Madison
State:  
WI
Zip Code: 53792
Conditions: HIV Infections
Purpose: This pilot study will investigate the safety and effect of etanercept in HIV infection by studying HIV replication and immune function (as measured by CD4 counts) in individuals with HIV infection.
Study summary:
Criteria: Inclusion Criteria: - Adults greater than 18 years of age with documented HIV infection - Highly active antiretroviral therapy (HAART) regimens as defined by the Department of Health and Human Services guidelines; stable regimens for 12 weeks. - CD4 greater than 200 at time of study enrollment - Stable monitoring labs (hematology survey with differential, ALT, creatinine) - Absolute neutrophil count within normal limits Exclusion Criteria: - AIDS defining illness within the last 6 months - Acute bacterial, viral, or fungal infection within the last 1 month, or history of recurring infections - Women who are pregnant or nursing - Hypersensitivity to etanercept - Previous use of etanercept - Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common skin cancers (non melanoma) - History of active or latent tuberculosis - History of demyelinating nerve disease - History of seizure disorder - Latex allergy - Subject has any of the following laboratory values within 30 days of baseline: - hemoglobin concentration < 10.0 g/dl for men and < 9.0 g/dl for women - platelet count < 75,000/mm3 - AST or ALT > 5x upper limit of normal (ULN) - serum creatinine > 2.5x ULN - serum pancreatic amylase > 1.5 ULN - Subject requiring treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferon - Subjects who chronically use any over-the-counter (OTC) or prescription medication (except vitamins) must not change the regimen or switch their medication within 3 days of drug administration and until discharged from the study.
Study is available at: University of Wisconsin Hospital and Clinics
Madison, WI 53792
United States

Primary Contact:
Andrew Urban, MD
Email: andrew.urban@med.va.gov
Phone: 608-256-1901

Secondary Contact:
Andrew Urban, MD
Email: Andrew.Urban@med.va.gov
Phone: 608-256-1901
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.